About Meditrial Editorial Team

This author has not yet filled in any details.
So far Meditrial Editorial Team has created 146 blog entries.

US: FDA exempts additional Class II devices from 510(k) requirements

2024-02-29T16:40:22+00:00July 23rd, 2020|Categories: Clinical Trial, Compliance, USA|Tags: , , |

The FDA ordered the exemption five types of Class II medical devices from 510(k) requirements. This decision aims at releaving manufacturers of those devices from some regulatory burden. Meditrial has extensive experience on regulatory matters relating to medical device [...]

Dr. Tocchi lecture for Weill Cornell Medicine

2024-02-02T10:42:51+00:00July 21st, 2020|Categories: Innovation, USA|Tags: , , , , |

How to build a Regulatory and Clinical Strategy. Meditrial is thrilled to partner with Weill Cornell Medicine to help biotechnology inventors be successful in globalhealth. Dr. Monica Tocchi will hold a lecture on regulatory. Register here https://lnkd.in/eT7WNWu For more information, click [...]

The European Commission updates on MDR implementation

2024-02-29T14:40:29+00:00July 20th, 2020|Categories: Clinical Trial, Compliance, Europe, MDR|Tags: , , , , |

The European Commission over the past week provided several updates on the implementation of the Medical Device Regulation (MDR) and released a fact sheet explaining the information that will be available to the public about devices according to transparency [...]

EU agencies commends sponsors to ensure post-Brexit compliance with clinical trial rules

2024-02-02T11:58:44+00:00July 13th, 2020|Categories: Clinical Trial, Compliance, Europe|Tags: , , , |

The European Commission together with the European regulatory agencies EMA (European Medicines Agency) and HMA (Heads of Medicine), released a statement to urge sponsors to comply with clinical trials rules after Brexit. The deadline for compliance is 31st December [...]

US: FDA plans to resume on-site domestic inspections as of 20 July 2020

2024-02-29T16:53:39+00:00July 13th, 2020|Categories: Clinical Trial, Covid-19, USA|Tags: , , , |

The Food and Drug Administration (FDA) announced the plan to resume on-site domestic inspections beginning the week of 20 July 2020. The resume process will be different in each state according to local rules and epidemiological situation. Moreovoer, a [...]

UK: Changes to amendment submission to HRA/MREC

2024-02-29T15:14:45+00:00July 8th, 2020|Categories: Clinical Trial, Europe, UK|Tags: , , |

On 2 June 2020 changes were introduced in the Integrated Research Application System (IRAS) to the way amendments are notified to Research Ethics Committees and NHS/HSC in the UK: Project-based research should now prepare amendments using the Amendment Tool. Amendments [...]

EU: Availability and capacity of notified bodies to carry out conformity assessments for COVID-19 related medical devices and in vitro diagnostic medical devices

2024-02-02T12:24:26+00:00July 8th, 2020|Categories: Covid-19, Europe|Tags: , , |

The European Commission (EC) conducted a survey in order to quantify lead times for conformity assessment for the various routes by which COVID-19-related medical devices may be placed on the market in the EU and for which notified bodies [...]

The European Commission launched COVID-19 In Vitro Diagnostic Devices and Test Methods Database

2020-07-07T07:57:08+00:00July 7th, 2020|Categories: Compliance, Covid-19, Europe|Tags: , , |

The European Commission launched the JRC COVID-19 In Vitro Diagnostic Devices and Test Methods Database. The objective of this database is to collect in a single place all publicly available information on performance of CE-marked in vitro diagnostic medical devices [...]

EMA: Points to consider on implications of COVID-19 on methodological aspects of ongoing clinical trials

2024-02-02T11:53:30+00:00July 2nd, 2020|Categories: Clinical Trial, Covid-19, Europe|Tags: , , |

The European Medicine Agency (EMA) released a guidance to illustrate some points to consider on implications of COVID-19 on methodological aspects of ongoing clinical trials. "At this point in time it is not possible to provide general advice on [...]

US: FDA published Q&A guidance on the effects of the COVID-19 emergency on formal meetings and user fee applications for medical devices

2024-02-29T17:05:07+00:00June 24th, 2020|Categories: Clinical Trial, Covid-19, Regulatory, USA|Tags: , , , , |

FDA published a Q&A document to respond frequently asked questions from submitters and applicants on regulatory matters and issues relating to medical devices arising from  the COVID-19 public health emergency. This guidance addresses the following: Meetings with Industry MDUFA [...]

Go to Top